| Literature DB >> 30456592 |
Lohit Garg1, Manasvi Gupta2, Syed Rafay Ali Sabzwari3, Sahil Agrawal4, Manyoo Agarwal5, Talha Nazir3, Jeffrey Gordon3, Babak Bozorgnia3, Matthew W Martinez3.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.Entities:
Keywords: Antiarrhythmic agents; Atrial fibrillation; Hypertrophic cardiomyopathy; Treatment
Mesh:
Substances:
Year: 2019 PMID: 30456592 DOI: 10.1007/s10741-018-9752-6
Source DB: PubMed Journal: Heart Fail Rev ISSN: 1382-4147 Impact factor: 4.214